CTLA4 and melanoma: A lack of IFN-γ pathway genes was found in the nonresponders to anti-CTLA-4 therapy (ipilimumab), and inactivation of the IFN-γ receptor, IFNGR1, caused the resistance to anti-CTLA-4 treatment in mice with melanoma [29].